Patents by Inventor Sherin Salaheldin Abdel-Meguid

Sherin Salaheldin Abdel-Meguid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME
    Publication number: 20220031665
    Abstract: Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 3, 2022
    Inventors: Shaker A. Mousa, Nabil A. Elshourbagy, Harold V. Meyers, Sherin Salaheldin Abdel-Meguid
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10947220
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 16, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10899748
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
    Publication number: 20200262822
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases
    Publication number: 20190270729
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: June 19, 2017
    Publication date: September 5, 2019
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
    Patent number: 10131637
    Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 20, 2018
    Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher Education
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20180079730
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 9682085
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 20, 2017
    Assignee: Shifa Biomedical Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa
  • ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20160256467
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa
  • ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATEMNT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20150374710
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Application
    Filed: March 11, 2014
    Publication date: December 31, 2015
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa
  • ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES
    Publication number: 20150376139
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: March 11, 2014
    Publication date: December 31, 2015
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Method of inhibiting cathepsin K
    Patent number: 6274336
    Abstract: A novel cathepsin K crystalline stucture is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: August 14, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Renee Louise Desjarlais, Cheryl Ann Janson, Ward Whitlock Smith, Jr., Baoguang Zhao
  • Proteases compositions capable of binding to said site, and methods of use thereof
    Patent number: 6083711
    Abstract: Novel herpes viral protease crystalline structures are identified which have an active site formed by the three amino acids Ser, His and His. Also disclosed are methods of identifying inhibitors of these proteases and/or active sites.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: July 4, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Xiayang Qiu, Ward Whitlock Smith, Jr., Cheryl Ann Janson, Susan S. Hoog, Jeffrey Culp, Christine Marie Debouck
  • Proteases, compositions capable of binding to said site, and methods of use thereof
    Patent number: 6008033
    Abstract: Novel herpes viral protease crystalline structures are identified which have an active site formed by the three amino acids Ser, His and His. Also disclosed are methods of identifying inhibitors of these proteases and/or active sites.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: December 28, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Xiayang Qiu, Ward Whitlock Smith, Jr., Cheryl Ann Janson, Susan S. Hoog, Jeffrey Culp, Christine Marie Debouck